Reap Consulting discusses how patient compliance to prescription medications continues to be a global problem costing society billions, and resulting in unnecessary suffering for millions of people every year.
Shutterstock - Mulad Images
The pharmaceutical industry devotes extraordinary resource to ensuring that medicines work. Clinical development programmes spanning a decade or more, regulatory submissions of tens of thousands of pages, and manufacturing processes of near-absolute precision are all marshalled in service of a single goal: a medicine that is safe and effective. And yet, a medicine can only work if the patient takes it correctly. This is almost too obvious to state — and yet non-compliance with prescribed medication regimens remains one of the most persistent and most costly unresolved problems in global healthcare.
The WHO's data on long-term therapies points to compliance levels of around 50%, a figure that has proven remarkably resistant to improvement over many decades of awareness and intervention. In Europe alone, approximately 200,000 deaths per year are attributed to non-compliance, at an estimated annual cost to the healthcare system of €125 billion. In Germany, the direct cost of non-compliance has been placed at a minimum of €10 billion per year. These are not abstract statistics; they represent missed treatment outcomes, avoidable hospitalisations and, in the most serious cases, preventable deaths.
What makes this particularly striking is that the primary packaging for the world's most widely used oral dose medicines — the pharmaceutical blister pack — sits at the precise point of consumption. The patient handles it every day. It is the last interface between the manufacturer and the moment of treatment. And in the vast majority of cases, it communicates almost nothing: a batch number, an expiry date, and perhaps the product name embossed or printed in a single colour on the lid foil. The dosing schedule, the precautions, the instructions that determine whether the medicine is taken correctly —all of these are relegated to the package insert and the secondary carton. Documents that may have been discarded at the pharmacy, or that the patient stopped reading after the first prescription.
The scale of non-compliance
Non-compliance with medication is not confined to developing healthcare systems, nor to patients with limited education or complex social circumstances. Studies conducted across Europe and North America consistently demonstrate that failure to take medicines correctly is widespread, spanning therapy areas, patient demographics, and levels of healthcare sophistication. For chronic conditions requiring long-term pharmacotherapy, the compliance picture is particularly sobering. But short-term treatments are far from immune to the problem, and in some respects, they present a more tractable challenge — because the failure modes are well understood.
Research conducted in community pharmacy settings in Poland, using a rigorous multicentre randomised controlled methodology, evaluated compliance amongst patients prescribed short-course antibiotic therapy. This is a setting of considerable clinical significance: incomplete antibiotic courses not only risk treatment failure for the individual patient, but contribute directly to the global crisis of antimicrobial resistance. In the control group, receiving standard pharmacy practice without additional communication aids, 15.7% of patients discontinued treatment before completing the prescribed course. The most commonly cited reason was simply that their symptoms had improved and they had assumed the medicine was no longer necessary.
This finding is not unique to antibiotics, nor to Poland. Across therapy areas, patients commonly misremember dosing schedules, underestimate the importance of completing a course, confuse one medicine with another when managing multiple prescriptions simultaneously, or lose confidence in a treatment whose purpose they do not fully understand. The consequences extend well beyond the individual: suboptimal therapeutic outcomes, increased disease recurrence, unnecessary repeat prescriptions, and avoidable secondary care episodes all flow from the same upstream failure of communication.
The dependency of compliance on patient understanding has been extensively documented. Medication leaflets are frequently written at a readability level that exceeds the health literacy of a significant proportion of the patient population, and elderly patients — for whom polypharmacy is both common and consequential — are particularly vulnerable. The result is that even where information is technically provided, it may not be understood, recalled, or acted upon at the moment it is needed.
Existing approaches and their limitations
The pharmaceutical industry and its packaging suppliers have not been indifferent to the compliance challenge. A range of solutions has been developed over the years, most of them well-intentioned, some of them genuinely useful for specific patient populations — but none of them without significant drawbacks of cost, complexity, or applicability.
At the more complex end of the spectrum, calendar blisters and compliance packaging formats — blisters with days of the week embossed or printed on the lid foil, or wallet-format cartons with individual tearable compartments for each dose — provide a structured reminder system for the patient. These are most commonly seen in oral contraceptives, where the daily dosing cycle and the need for dose-tracking are well established, and the added packaging cost is absorbed into a high-value, branded product. For the broader pharmaceutical market, however, calendar blisters represent a significant step-up in complexity: they require a dedicated blister format, specific tooling, and printing registrations that must be maintained across the full production run. The secondary carton must accommodate the modified blister geometry. The costs are higher, the supply chain is more specialised, and the format is only easily applicable to regular, fixed-dose daily regimens.
Multi-compartment compliance aids — the weekly pill organisers and Dosette boxes familiar from community pharmacy and domiciliary care settings — serve an important function for patients managing complex multi-drug regimens, particularly the elderly. But they require a healthcare professional or carer to fill them, they remove the medicine from its original labelled packaging, and they are by definition a downstream intervention, dependent on an organised support system around the patient. They do not address the point-of-manufacture or point-ofdispensing communication failure.
Reminder packaging in the form of enhanced secondary cartons —multi-panel wallet cartons with compliance charts, QR codes linking to digital dosing reminders, or leaflets with tear-off diary sections — has been adopted by some pharmaceutical companies for specific products. These solutions can be effective, but they are expensive to produce, require a change to the entire secondary packaging specification, and their effectiveness depends on the patient keeping and consulting the carton throughout the course of treatment. In practice, many patients decant tablets from their blister at the dispensing point and discard the carton immediately.
Digital compliance tools — smartphone applications, connected packaging with NFC tags, and electronic blister monitors that record the time and date of each cavity push — represent the leading edge of compliance technology. For certain high-value therapy areas, particularly oncology and transplant medicine, the investment in these technologies can be justified by the clinical and economic consequences of non-compliance. For the broad market of everyday prescriptions — antibiotics, antihypertensives, statins, analgesics — the cost and implementation burden of connected packaging remains prohibitive, and adoption has been limited accordingly.
What all of these approaches share is a degree of additional complexity, cost, and supply chain disruption that makes them suitable for specific applications but impractical as a general solution. The compliance problem, affecting as it does the full breadth of the prescription medicine market, arguably calls for something different: an intervention that is universal in its applicability, minimal in its implementation burden, negligible in its cost increment, and effective at the point where it matters most — in the hands of the patient, at the moment they are about to take their medicine.
The role of pictograms in patient communication
Pictograms — standardised visual symbols conveying medical information — have been studied as a tool for improving medication compliance and patient understanding for several decades. The evidence base is broadly supportive of their effectiveness, and the mechanism of action is well understood: visual information is processed faster than text, is more readily recalled, and is accessible to patients across literacy levels and language barriers. For the ageing populations of Europe and North America, where health literacy may be limited and polypharmacy is common, these attributes are particularly valuable.
A multicentre pilot study conducted in Polish community pharmacies evaluated the comprehension of a validated series of pharmaceutical pictograms among patients aged 65 and above. Using structured face-to-face interviews with 68 patients across five different regions, the study found that 22 out of 35 evaluated pictograms achieved the required comprehension threshold of 66% or above — the standard set by ISO 9186 for validated graphical symbols. Importantly, all validated pictograms also passed shortterm memory recall tests, suggesting that once a patient has understood a pictogram, they are able to retain its meaning. Patients were clear in their feedback that coloured pictograms were more effective than monochrome designs, and that simple, unambiguous imagery combined with a short explanatory text performed best. The study also found that pictograms addressing dosing schedule — when and how many times to take the medicine — were among the most readily understood and recalled.
The randomised controlled trial that followed this pilot directly evaluated the practical utility of pictograms in the context of antibiotic therapy. Patients in the study group, where pictograms were placed on the external packaging and used during the pharmacy consultation, showed measurably higher satisfaction with the information they had received: the Net Promoter Score for pharmacy practice supported by pictograms was 71.3%, versus 51.5% in the standard care group, a statistically significant difference. Patients supported by pictograms were also twice as likely to be strong advocates for the pharmacy service. The composite compliance endpoint was achieved more frequently in the pictogram group, and while the difference did not reach statistical significance — a result the authors attributed primarily to the limited sample size — the direction and magnitude of the effect were consistent across all measured outcomes.
The critical insight from this body of research is not simply that pictograms are effective, but that their effectiveness is greatest when they are located where the patient will actually encounter them: at the point of medication use, not on a leaflet they may never re-read. A patient who has been counselled by a pharmacist using a pictogram, and then sees that same symbol each time they push out a tablet, receives a consistent and reinforcing prompt at every dose. This is the point at which the blister pack itself becomes a compliance tool —and it is a point that has, until recently, been almost entirely neglected.
The regulatory and standards framework
One of the most frequently cited barriers to innovation in pharmaceutical packaging is regulatory uncertainty. It may therefore come as a reassurance that the use of pictograms on pharmaceutical packaging is not only permitted but explicitly contemplated within existing European legislation. EU Directive 2001/83/EC, the Community code relating to medicinal products for human use, addresses this directly in Article 62:
"The outer packaging and the package leaflet may include symbols or pictograms designed to clarify certain information... and other information compatible with the summary of the product characteristics which is useful for health education, to the exclusion of any element of a promotional nature."
This provision makes clear that pictograms are a legitimate element of pharmaceutical packaging within the EU regulatory framework, provided they meet conditions of clarity and accuracy consistent with the approved product information. At national level, the Austrian Medicines Law (Arzneimittelgesetz) goes further, mandating in §17 that the medicine name must remain readable until the last dosage form is taken — a requirement that the standard plain aluminium blister base does not always satisfy after deep forming, but that a printed base foil addresses directly.
In the United States, the Pharmacopeia has taken a systematic approach to this area that is worth highlighting for its practical utility. The USP pictogram library makes available 81 standardised, pre-validated pictograms free of charge, covering a broad range of dosing instructions, administration routes, precautions, and indication categories. These range from clear dosing schedule symbols — take twice a day, take in the morning, take at bedtime — to cautionary pictograms covering drug interactions, pregnancy, driving impairment, and child safety, through to indication-specific images for conditions including heart disease, hypertension, and respiratory complaints. For any pharmaceutical company wishing to implement pictogram-based communication, this library represents a ready-made, validated resource that removes the need for the development and clinical validation of bespoke designs, and the associated cost and timeline that has historically acted as a barrier to adoption.
The regulatory enablers are therefore already in place. The pictogram vocabulary exists and is validated. What has been missing is a practical, commercially straightforward means of placing those pictograms on the primary blister pack itself — at the point where patient contact is guaranteed, every single time a dose is taken.
A simpler solution: The printed blister base foil
The solution that addresses this gap is, in its concept, straightforward: printing pictograms and dosing information directly onto the base foil of the blister pack, so that the information is present on the primary packaging at the point of use, visible and legible to the last tablet. What has made this impractical in the past, and what makes it commercially viable now, is worth understanding in some detail.
Printing on pharmaceutical blister base materials is not new in principle. Coloured and printed cold form foil has been commonplace in India for many years — representing as much as 20% of overall cold form foil demand in that market — where pharmaceutical companies have recognised that the limited number of qualified cold form foil producers makes a printed primary pack a meaningful anti-counterfeit measure as well as a brand differentiator. In Europe and the Americas, by contrast, over 98% of cold form foil in commercial use remains entirely unprinted. Printed PVC and PVC/PVdC base films are similarly rare, despite the technical feasibility having existed for some time.
The barrier has not been technical; it has been commercial and organisational. Printing onto a blister base material requires either a reverse-print approach — applying ink to the film prior to lamination, sandwiching it between layers — or surface printing with a protective overcoat. Both methods introduce additional steps into the converting process and raise questions that require validation: ink adhesion after deep forming, the integrity of the print through the forming and sealing process, and, most critically for a primary pharmaceutical contact material, the absence of any risk of ink migration towards the drug product.
These concerns are now well addressed by modern materials and lamination technology. The most technically robust approach — and the one that has been developed and patented by at least one specialist European converter — involves printing a thin plastic layer and laminating it against the customer's standard deep-forming base foil, whether PVC, PVC/PVdC, or cold form aluminium. The print is sandwiched inside the laminate structure, entirely isolated from both the outer surface and the drug-contacting inner surface. This construction eliminates the migration risk by design rather than by formulation, and the forming integrity of the base foil is unaffected because it remains the structural element of the laminate.
Critically, this solution is supplied to the pharmaceutical company as a direct drop-in replacement for their existing base foil. No change to the blister packaging line is required. No new tooling, no process revalidation of the packaging equipment, no modification to the secondary carton geometry. The printed foil arrives on the reel, in the same format as the unprinted equivalent, pre-registered to the cavity positions of the blister. For a purchasing team or packaging technologist, the specification change is modest; for a brand owner or compliance manager, the potential benefit is considerable.
The range of information that this approach can carry is extensive, and here the comparison with existing compliance packaging formats becomes particularly illuminating. A calendar blister requires a dedicated pack format, specialised tooling, and additional printing registration — it is inherently a new packaging development. A printed base foil requires none of these things. A compliance wallet carton involves a complete redesign of the secondary packaging specification and a significant cost premium — industry estimates place fully compliant calendar and wallet formats at between two and four times the cost of a standard blister-and-carton combination. A printed base foil adds a fraction of that cost. And where digital compliance packaging involves embedded electronics, app development, and patient onboarding, a pictogram on a blister base foil requires only that the patient can see it.
The content that can be printed spans the full range of compliance-relevant information. Dosing schedule pictograms — morning, noon, evening, at bedtime, with food, on an empty stomach — provide an immediate visual cue at every dose. Cautionary symbols — do not drive, avoid alcohol, not for use during pregnancy, keep out of reach of children — ensure that critical safety information is present on the primary pack rather than only on the carton that may have been discarded. Indication-specific imagery — a heart symbol for cardiac medicines, a lung for respiratory therapy, a head for neurological conditions — reinforces patient identification of the correct medicine, with particular value for elderly patients managing multiple concurrent prescriptions. The medicine name, printed alongside the pictogram, remains legible to the last dose, satisfying the regulatory requirement that has not always been met by the standard embossed or printed aluminium base.
The photograph below illustrates the commercial reality of this solution. Several blister packs, all produced from standard deep-drawn blister film of the kind used every day across the pharmaceutical industry, carry printed pictograms of clear, professional quality: clear indication symbols in full colour. These are not experimental prototypes; they are commercially available samples demonstrating what can be achieved within the constraints of a validated pharmaceutical packaging material.
The USP pictogram library, freely available and pre-validated, provides a ready-made resource for pharmaceutical companies wishing to implement this approach. For a product requiring a twice-daily dosing reminder, USP pictogram 3 (take twice a day with meals) or pictogram 4 (take twice a day) is available off the shelf, validated, and recognisable. For a product carrying a drowsiness warning, pictogram 50 (do not drive if this medicine makes you sleepy) or pictogram 72 (if this medicine makes you dizzy, do not drive) communicates the message without a word of text. For a cardiac medicine, pictogram 75 (for heart problems) provides immediate indication identification. The building blocks are already there.
The broader opportunity
It is worth pausing to consider why this approach has not already been more widely adopted, because the question is a reasonable one. The technology exists. The regulatory framework permits it. The evidence base for pictogram-based communication at point of use is established and broadly consistent. The cost increment is modest compared with existing compliance packaging solutions, and almost immaterial compared to the cost of the product, and the cost of non-compliance. And the potential clinical and commercial benefit is real.
Part of the answer lies in the conservatism of pharmaceutical packaging specifications, which are rightly resistant to change but can be slow to respond even to low-risk, low-cost improvements. A base film or foil specification, once validated and embedded in a marketing authorisation, requires effort to revise — and the impetus to do so must come from a brand owner or medical affairs team who see the compliance benefit, not from a purchasing team focused on continuity of supply.
Part of the answer also lies in supply chain inertia. The film and foil converters have limited commercial incentive to advocate for a more complex, higher-value product unless the pharmaceutical company creates the demand. And pharmaceutical companies, without a clear internal champion for primary-pack compliance innovation, tend to default to the established formats.
But the landscape is changing. Regulatory and payer pressure on pharmaceutical companies to demonstrate realworld effectiveness of their medicines — not just clinical efficacy in controlled trials — is increasing. Health technology assessors in several major markets are beginning to incorporate compliance data into their benefit assessments. As the evidence linking packaging communication to patient outcomes becomes more robust, the case for investing in primary-pack compliance tools becomes commensurately stronger.
For brand owners, a printed blister base carrying clear, validated pictograms offers a patient communication tool that is visible at every dose, language-independent, and — given the limited number of converters currently capable of producing this format to pharmaceutical quality standards — a meaningful differentiator that is difficult for generic competitors to replicate quickly. For purchasing teams, it offers a compliance solution at a fraction of the cost of calendar blisters or compliance wallet cartons, with no change to existing packaging line configurations. For medical affairs and regulatory teams, it offers a low-risk route to enhanced primary-pack communication that is explicitly supported by existing European and national legislation.
For packaging converters, the opportunity is perhaps the most immediately tangible. A differentiated, patentprotected product with a clear patient safety rationale, applicable to the broad market of pharmaceutical blister packaging, represents a compelling commercial proposition in a sector where pricing pressure is increasing. Converters with strong existing relationships in pharmaceutical blister packaging are well placed to offer this as a value-added service alongside their standard base film range.
Conclusion
The pharmaceutical blister pack is the most widely used primary packaging format for oral dose medicines in the world. Hundreds of billions of individual blisters are dispensed every year, each one representing a direct daily interaction between a patient and their medication. And yet the informational content of the blister base — the surface the patient sees every time they take a tablet — has remained essentially unchanged since the format was introduced in the 1960s.
The compliance challenge is well documented, the human and economic costs are substantial, and the existing solutions — calendar blisters, compliance cartons, pill organisers, digital compliance tools — are either too expensive, too complex, or too limited in their applicability to address the problem at the scale it demands. The printed blister base foil, carrying validated pictograms at the point of use, is not a complete answer to non-compliance — no single intervention is. But it is a practical, low-cost, process-compatible tool that works at the one moment that matters: when the patient is holding their medicine.
The regulatory framework already supports it. The pictogram vocabulary is already validated and freely available. The converting technology is commercially ready. The evidence that visual communication at point of use improves patient understanding and satisfaction is established and growing. For pharmaceutical companies and their packaging partners, the conditions for adoption are better today than they have ever been — and the patients who might benefit are taking their medicine right now.